• Profile
Close

Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma

American Journal of Clinical Oncology Jul 31, 2018

Abbott AM, et al. - Researchers assessed the hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) following regional therapy to the liver for metastatic melanoma. Significantly prolonged HPFS and PFS were seen in patients treated with percutaneous hepatic perfusion (PHP) vs chemoembolization (CE) or yttrium-90 (Y90). In patients treated with PHP, median OS was over double than seen in patients treated with Y90 or CE, however, it was significant only between PHP and Y90. On multivariate analysis, significant predictors of prolonged PFS were PHP treatment and lower tumor burden.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay